Combination therapy for resectable MSI-H stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy, anti-angiogenic therapy (which blocks blood vessel growth to tumors), and chemotherapy for people with a specific type of stomach cancer that is MSI-H/dMMR (meaning it has many mutations and may respond better to immunotherapy). The goal is to shrink the cancer and potentially make it removable by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and able to give written consent to join the study.
- Your cancer must be stomach or gastroesophageal junction adenocarcinoma (a specific type of cancer) that cannot be removed with surgery or has spread to other parts of the body.
- You must not have received any prior treatment for this stage of cancer from a needle biopsy: your tumor must have a PD-L1 score less than 1, which means low expression of a certain protein.
- You must have at least one measurable tumor (that can be seen on scans) and be in good general health (able to carry out daily activities with minimal help).
- You must not have had certain other cancers in the last 5 years, except for some early-stage skin or cervical cancers.
- You must not have had immunotherapy drugs like PD-1, PD-L1, or CTLA-4 inhibitors before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy for stomach cancer. The goal is to see if this combination can help shrink tumors and improve outcomes better than chemotherapy alone.
This trial is testing a combination of immunotherapy, anti-angiogenic (blood vessel blocker) therapy, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't spread yet. It is for those whose tumors have a low PD-L1 score and who haven't had treatment for the advanced cancer before.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for people with advanced gastric cancer that has a specific DNA repair problem (MSI-H/dMMR). It is for those who have not yet had any treatment for their advanced cancer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy (SOX) and radiation for stomach cancer that hasn't been treated before. The goal is to see if this approach can shrink tumors and help you live longer.
This study tests a combination of two immunotherapy drugs plus chemotherapy before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can help shrink stomach cancer and reduce the chance of it coming back. It is for people whose tumors have a specific genetic feature called MSI-H or dMMR, which often responds well to immunotherapy.
Hear when a new Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.